There are no Transcripts on AZNCF.
Tue, Aug. 19, 4:45 AM
- AstraZeneca (NYSE:AZN) says that the U.S. government has closed a probe that investigated a major clinical trial used to win marketing approval for the company's new heart drug Brilinta.
- Following the DOJ's investigation into the study last October, doubts have ensued over the medicine's future success.
- AstraZeneca argues that Brilinta can bring in $3.5B in annual sales, although until now the drug has not made any record performance.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
AZNCF vs. ETF Alternatives
Other News & PR